동물용 항생제 및 항균제 시장 : 유형별, 동물 유형별, 투여 경로별, 제형별, 최종 사용자별, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Animal Antibiotics & Antimicrobials Market is projected to grow by USD 7.41 billion at a CAGR of 7.08% by 2032.

Animal Antibiotics & Antimicrobials Market Introduction

Animal antibiotics and antimicrobials remain essential to veterinary medicine, food-animal productivity, and companion-animal health, but their role is being redefined by antimicrobial resistance, tighter stewardship expectations, and changing consumer demand for responsibly produced protein. The market spans medically important antibiotics, ionophores, sulfonamides, tetracyclines, macrolides, beta-lactams, fluoroquinolones, and other veterinary antimicrobial classes used under regulated conditions to treat, control, and prevent bacterial disease in livestock, poultry, aquaculture, and pets.

The sector is now shaped by a clear public-health mandate: preserve antimicrobial effectiveness while sustaining animal welfare and food security. WHO identifies antimicrobial resistance as one of the top global public-health threats, while WOAH, FAO, and national regulators continue to promote surveillance, veterinary oversight, responsible prescribing, and prudent-use frameworks. As a result, growth opportunities are increasingly tied to prescription-based access, diagnostics-led treatment, residue compliance, farm biosecurity, and alternatives that reduce disease pressure without undermining therapeutic availability.

Transformative Shifts in the Animal Antimicrobials Landscape

The animal antimicrobials landscape is shifting from volume-led medication toward evidence-based, need-specific therapy. In the United States, FDA policy removed production uses of medically important antimicrobials from feed and water labels and brought remaining therapeutic uses under veterinary oversight. In the European Union, legislation prohibits antibiotic growth promotion and restricts routine prophylaxis, reinforcing a market direction centered on accountable prescribing and farm-level prevention.

At the same time, producers face persistent disease risks from intensive farming, climate-linked pathogen pressure, cross-border animal movement, and expanding aquaculture. These conditions are accelerating demand for rapid diagnostics, vaccination programs, precision dosing, traceability systems, and integrated herd-health services. Suppliers that combine compliant antimicrobial portfolios with stewardship support, residue management, and outcome-based veterinary guidance are better positioned than those relying on undifferentiated product access.

Cumulative Impact of Artificial Intelligence on Veterinary Antimicrobials

Artificial intelligence is becoming a practical enabler of antimicrobial stewardship rather than a replacement for veterinary judgment. AI-supported disease surveillance can combine farm records, production data, environmental signals, laboratory results, and treatment history to detect abnormal morbidity patterns earlier. This helps veterinarians target testing, isolate affected groups, and reduce unnecessary blanket treatment.

AI is also improving antimicrobial decision support through predictive analytics, resistance-pattern monitoring, image-based diagnostics, and optimization of dosage and withdrawal-period compliance. In research and development, machine learning is used to screen antimicrobial candidates, evaluate combinations, and identify resistance markers. The most immediate commercial value lies in AI-enabled precision livestock management: fewer treatment failures, better documentation, stronger audit readiness, and more defensible antibiotic use across complex supply chains.

Key Regional Insights for Animal Antibiotics & Antimicrobials

Asia-Pacific is a high-priority region because it combines large livestock populations, fast-growing poultry and aquaculture industries, and increasing regulatory attention to antimicrobial resistance. China, India, Japan, South Korea, and Australia are advancing surveillance, veterinary oversight, and residue-control systems at different speeds, creating demand for compliant animal antibiotics, veterinary antimicrobials, diagnostics, and farm-management tools that support responsible use.

North America is defined by mature veterinary distribution, strong food-safety enforcement, and established prescription oversight. The United States and Canada continue to emphasize medically important antimicrobial stewardship, while Mexico remains important for integrated North American protein supply chains. Latin America, led by Brazil and Mexico, balances export-driven residue compliance with high disease-management needs in cattle, poultry, and swine, making biosecurity, therapeutic reliability, and regulatory documentation central to market participation.

Europe is among the strictest regulatory environments, with EU rules shaping reduced routine use, stronger monitoring, and preference for prevention-led animal health. The Middle East is investing in food security, dairy, poultry, and camel health, while GCC countries are strengthening import standards and veterinary infrastructure. Africa presents long-term potential due to herd expansion and food-security needs, but market development depends on veterinary access, cold-chain reliability, diagnostics capacity, residue monitoring, and control of informal antimicrobial channels.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly important for poultry, swine, and aquaculture health as governments modernize veterinary regulation and food-safety systems. The region's opportunity is tied to practical stewardship models that work across smallholders, integrators, and export-oriented producers. BRICS countries represent a major share of global animal protein production and demand, with Brazil, China, India, and Russia requiring scalable disease-control strategies that align productivity with antimicrobial resistance mitigation.

The European Union remains a benchmark for antimicrobial governance through harmonized restrictions, surveillance, and farm-to-fork policy alignment. G7 countries influence global standards through advanced research, pharmaceutical regulation, One Health antimicrobial resistance action plans, and veterinary innovation, while NATO members overlap with many high-income markets where supply-chain resilience, biosecurity, and food-system security have gained strategic importance. GCC markets are smaller in livestock volume than Asia-Pacific or Latin America, but they are strategically relevant because of food-security investment, premium dairy and poultry operations, import dependence, and rising expectations for regulated veterinary care.

Key Country Insights for Animal Antibiotics & Antimicrobials

The United States leads in veterinary oversight, companion-animal care, and regulated livestock antimicrobial use, with FDA stewardship policies shaping market access. Canada follows a similar prudent-use direction, while Mexico's role in North American beef, pork, and poultry trade makes residue compliance and disease control central. Brazil is one of the world's most influential animal-protein exporters, making veterinary antimicrobials, biosecurity, and compliance systems critical to poultry, beef, and swine competitiveness.

In Europe, the United Kingdom, Germany, France, Italy, and Spain operate under mature veterinary frameworks with strong attention to antimicrobial reduction, monitoring, and prevention. Germany and France emphasize high-standard veterinary medicine and livestock productivity, while Spain and Italy remain significant livestock and companion-animal markets. Russia has substantial poultry, swine, and cattle production needs, with domestic supply resilience, veterinary access, and disease surveillance influencing market behavior.

China and India are pivotal because of scale, livestock diversity, and rising demand for safe animal protein. China continues to strengthen veterinary regulation and food-safety enforcement, while India's dairy, poultry, and aquaculture sectors require accessible veterinary solutions and responsible-use education. Japan and South Korea are advanced, quality-focused markets with strong regulatory expectations and sophisticated livestock and companion-animal care systems. Australia combines export-oriented livestock production with strict biosecurity and residue standards, supporting demand for compliant therapeutics and antimicrobial stewardship tools.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize portfolios that align with veterinary oversight, resistance-risk management, and documented therapeutic need. This includes investing in narrow-spectrum options where appropriate, improving label clarity, strengthening pharmacovigilance, and supporting veterinarians with susceptibility testing, treatment protocols, and digital recordkeeping.

Organizations should also build growth beyond the molecule by integrating diagnostics, vaccines, biosecurity advisory services, microbiome-support solutions, and precision-farming platforms. Market access teams need region-specific compliance strategies, especially for EU restrictions, FDA requirements, export residue standards, and emerging-market stewardship programs. Partnerships with laboratories, producer groups, universities, and regulators can improve evidence generation and reinforce trust with retailers, food companies, veterinarians, producers, and consumers.

Research Methodology

The research approach is grounded in a comprehensive framework that leverages verified public-health, veterinary, regulatory, and trade sources. Core references include guidance and surveillance frameworks from the World Health Organization, the World Organisation for Animal Health, the Food and Agriculture Organization, national veterinary authorities, the U.S. Food and Drug Administration, the European Medicines Agency, and regional antimicrobial resistance action plans.

The analysis triangulates regulatory developments, animal-production trends, antimicrobial stewardship policies, veterinary distribution dynamics, food-safety requirements, residue-control expectations, and disease-management needs across regions and countries. Insights are evaluated for commercial relevance, policy consistency, and applicability to animal antibiotics and antimicrobials, with an emphasis on evidence-backed themes rather than unsupported market-size, market-share, or forecasting claims.

Conclusion

The animal antibiotics and antimicrobials market is entering a more disciplined phase in which growth depends on responsible access, measurable outcomes, and alignment with global antimicrobial resistance priorities. Therapeutic antimicrobials will remain indispensable for animal welfare and food security, but their use will be increasingly guided by diagnostics, surveillance, veterinary authorization, and prevention-first herd-health strategies.

Manufacturers, distributors, veterinarians, and producers that embrace stewardship as a commercial advantage can strengthen market resilience. The strongest opportunities will come from compliant antimicrobial portfolios, AI-enabled decision support, regional regulatory expertise, and integrated solutions that reduce disease burden while preserving the effectiveness of critical veterinary medicines.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Animal Antibiotics & Antimicrobials Market, by Class

• 7.1. Aminoglycosides
  • 7.1.1. Gentamicin
  • 7.1.2. Neomycin
  • 7.1.3. Streptomycin
• 7.2. Beta Lactams
  • 7.2.1. Cephalosporins
  • 7.2.2. Penicillins
• 7.3. Fluoroquinolones
  • 7.3.1. Ciprofloxacin
  • 7.3.2. Enrofloxacin
  • 7.3.3. Marbofloxacin
• 7.4. Macrolides
  • 7.4.1. Erythromycin
  • 7.4.2. Spiramycin
  • 7.4.3. Tilmicosin
  • 7.4.4. Tylosin
• 7.5. Sulfonamides
  • 7.5.1. Sulfadimethoxine
  • 7.5.2. Sulfamethazine
• 7.6. Tetracyclines
  • 7.6.1. Chlortetracycline
  • 7.6.2. Doxycycline
  • 7.6.3. Oxytetracycline
  • 7.6.4. Tetracycline

8. Animal Antibiotics & Antimicrobials Market, by Animal Species

• 8.1. Aquaculture
• 8.2. Cattle
• 8.3. Companion Animals
• 8.4. Poultry
• 8.5. Swine

9. Animal Antibiotics & Antimicrobials Market, by Administration Route

• 9.1. Feed Additives
• 9.2. In Ovo
• 9.3. Injectable
• 9.4. Oral
• 9.5. Topical
• 9.6. Water Soluble

10. Animal Antibiotics & Antimicrobials Market, by Formulation

• 10.1. Bolus
• 10.2. Liquid
• 10.3. Powder
• 10.4. Premix

11. Animal Antibiotics & Antimicrobials Market, by End User

• 11.1. Commercial Farms
• 11.2. Veterinary Hospitals & Clinics
• 11.3. Research Institutions

12. Animal Antibiotics & Antimicrobials Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. Animal Antibiotics & Antimicrobials Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Animal Antibiotics & Antimicrobials Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Animal Antibiotics & Antimicrobials Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AdvaCare Pharma LLP
• 17.2. Ashish Life Science Private Limited
• 17.3. Bayer AG
• 17.4. Bimeda Holdings Limited
• 17.5. Boehringer Ingelheim International GmbH
• 17.6. Ceva Sante Animale S.A.
• 17.7. China Animal Husbandry Industry Co., Ltd
• 17.8. Dechra Pharmaceuticals PLC
• 17.9. ECO Animal Health Group Plc
• 17.10. Elanco Animal Health Incorporated
• 17.11. Endovac Animal Health
• 17.12. Hester Biosciences Limited
• 17.13. HIPRA S.A.
• 17.14. Huvepharma EOOD
• 17.15. Indian Immunologicals Ltd
• 17.16. Inovet Group
• 17.17. Intas Animal Health
• 17.18. Kyoritsu Seiyaku Corporation
• 17.19. Lutim Pharma Pvt Ltd
• 17.20. Meiji Holdings Co., Ltd
• 17.21. Merck & Co., Inc
• 17.22. Norbrook Laboratories Limited
• 17.23. Ouro Fino Saude Animal
• 17.24. Phibro Animal Health Corporation
• 17.25. SeQuent Scientific Ltd
• 17.26. Vetoquinol S.A.
• 17.27. Vetsfarma Ltd
• 17.28. Virbac S.A.
• 17.29. Zoetis Inc
• 17.30. Zydus Animal Health And Investments Limited